Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this ...

Is Pfizer's 6% yield a rare opportunity hiding in plain sight, or are investors overlooking a major risk that could reshape ...

Pfizer is rated a Strong Buy, offering a nearly 7% forward dividend yield, which is highly likely safe. PFE's revenue has stabilized, management is delivering cost savings, and a recent drug pricing ...

Pfizer remains a 'Buy' at current low valuation multiples, but faces significant headwinds from an impending patent cliff through 2030. Pfizer's top-line growth is challenged by steep declines in ...

Pfizer Inc. (NYSE:PFE) is one of the best immunotherapy stocks to buy according to hedge funds. On February 12, Daiwa ...

Pfizer Inc. (NYSE:PFE) is one of the best affordable healthcare stocks to buy now. Scotiabank analyst Louise Chen reiterated a Buy rating on Pfizer Inc. (NYSE:PFE) on December 17 and set a price ...

We recently published Top 10 Trending Stocks as Famous Billionaire Predicts Massive AI Stock Rally Before Bubble Burst. Pfizer Inc (NYSE:PFE) is one of the trending stocks. Analysts are getting ...

A U.K. marketing watchdog has sanctioned Sanofi after ruling its CEO Paul Hudson may have undermined the U.K. government’s vaccine program by making “bold claims” about a procurement choice. Pfizer ...

In the last six months Pfizer’s stock (NYSE: PFE) has underperformed Merck (NYSE: MRK) and Johnson & Johnson (NYSE: JNJ) primarily due to waning demand for its COVID-19 products, a significant ...

Novo Nordisk’s CEO was magnanimous about Pfizer’s victory in last year’s bidding war over an obesity biotech, but the Danish pharma is making no secret of the fact it remains on the lookout for a ...